Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Blood Adv. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482.


  1. Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant.

  2. Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
  • Humans
  • Sulfonamides* / therapeutic use


  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • venetoclax